[Dopamine in the pathogenesis of normogonadotropic amenorrhea].
A total of 108 patients with normo-gonadotropic amenorrhea and 25 normal females were investigated. Three dopamine-dependent parameters were under study: maximum range of changes in the blood levels of luteinizing hormone (LH) and follicle-stimulating hormone, hypophyseal response to thyrotropin releasing factor (TRF) and prolactinemia-dependent therapeutic effect of bromocriptine. Significantly increased range of the serum gonadotropin levels, increased reaction of hypophyseal thyrotropic hormone to TRF and higher therapeutic efficiency of bromocriptine was revealed in hyperprolactinemic patients versus those with normo-gonadotropic amenorrhea. The results obtained are indicative of the decreased dopaminergic tension of the tuberoinfundibular system in hyperprolactinemic amenorrhea and increased one in normoprolactinemic patients. In 15 out of 32 normoprolactinemic patients bromocriptine therapy normalized their menstrual cycles. The range of spontaneous changes in the blood levels of LH was supposed to be a prognostic criterion for the assessment of bromocriptine therapeutic efficiency. A relative hypophyseal deficiency of dopamine was suggested in some of normoprolactinemic patients.
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D001971:Bromocriptine / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology*; D005260:Female; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000188:drug therapy; D007775:Lactation Disorders / Q000097:blood / Q000188:drug therapy; D011247:Pregnancy; D012016:Reference Values; D013973:Thyrotropin-Releasing Hormone; D013997:Time Factors
D006065:Gonadotropins, Pituitary; D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D004298:Dopamine
Dofamin v patogeneze normogonadotropnoĭ amenorei.